AUTHORS
George Kladis, N/A, Nienke Goedhart, PhD2, Christos Adamopoulos, PhD3, Afroditi Katsarou, MSc4, Ruud Ruiter5, Thomas Baardemans6, Marie Jose Kersten, MD7, Arnon Philip Kater, MD, PhD8, Richard Groen, PhD9, Poulikos I. Poulikakos, PhD10, Maria Themeli, MD PhD11
AFFILIATIONS
1 Amsterdam Umc-Cancer Center, Amsterdam, Netherlands
2 Amsterdam Umc-Cancer Center, Amsterdam, Netherlands
3 National And Kapodistrian University Of Athens, Athina, Attiki, Greece
4 Amsterdam Umc-Cancer Center, Amsterdam, Netherlands
5 Amsterdam Umc-Cancer Center, Amsterdam, Netherlands
6 Amsterdam Umc-Cancer Center, Amsterdam, Netherlands
7 Amsterdam Umc-Cancer Center, Amsterdam, Netherlands
8 Amsterdam Umc-Cancer Center, Amsterdam, Netherlands
9 Amsterdam Umc-Cancer Center, Amsterdam, Netherlands
10 Icahn School of Medicine, New York, New York, United States
11 Amsterdam Umc-Cancer Center, Amsterdam, Netherlands
ABSTRACT
Background
CAR T-cell therapy has transformed the treatment of relapsed/refractory multiple myeloma, yet a sizable patient fraction relapses, due to loss of CAR T-cell functional persistence. Maintenance of less-differentiated and fitness-enhanced phenotype of CAR T cell products, through transient pharmacologic pretreatment, can improve long term persistence. CDK4/6 inhibition promotes T-cell memory/stemness, while IKZF1/3 (Ikaros/Aiolos) degradation by immunomodulatory drugs (IMiDs) augments effector function and cytokine production.MS140 is a novel bifunctional degrader (a palbociclib–pomalidomide PROTAC) that simultaneously degrades CDK4/6 and IKZF1/3, combining the functionality of the single moieties. In this study we investigated whether the dual activity of MS140 pretreatment synergistically enhances the functional, transcriptional and metabolic CAR T-cell profile.
Methods
MS140, palbociclib (CDK4/6 inhibitor), pomalidomide (IKZF degrader), or vehicle were added for 3-4 days during manufacturing of healthy-donor-derived anti-BCMA CAR-T cells. To determine functional persistence in vitro, CAR-T cells were serially re-stimulated weekly with irradiated MM1.S MM target cells for up to 4 weeks (Day 28). Each week we quantified CAR-T expansion and memory phenotype by flow cytometry, antigen-specific cytotoxicity by luciferase bioluminescence across different effector:target (E:T) ratios, and cytokine production (BD CBA). Target-protein degradation was confirmed by western blot, and transcriptional and metabolic reprogramming was profiled by bulk RNA-seq of CAR-T cells and CENCAT, respectively, with or without stimulation with MM1.s tumor cells (3 donors; DESeq2 and gene-set enrichment analysis).
Results
CAR T cells production in the presence of MS140, resulted in G0/G1 cell cycle arrest and reduced yield of manufactured cells, but retained a significantly higher number of CD62L+ naïve/memory cells (p<0.05). MS140 did not impair CAR-T potency, as baseline cytotoxicity was equivalent to control untreated CAR T cells (56% vs 53% specific lysis at 1:1; p=0.62). Differences in cytotoxicity and proliferation emerged only under serial antigen stimulation, with MS140 significantly preserving serial cytotoxicity. Specifically, at day 28, MS140-treated CAR-T cells killed 63% of targets (2:1) compared to 12% for control, 0% for palbociclib and 54% for pomalidomide (all p<0.05). Cumulative expansion from day 14 was greatest in the MS140 arm, reaching approximately 9-fold by day 21 versus 3-fold for control and 4-fold for palbociclib, and comparable to pomalidomide (approximately 8-fold). Both control- and palbociclib-treated cells subsequently contracted, whereas MS140 and pomalidomide sustained expansion up to day 28. Treatment with MS140 also increased antigen-specific IL-2 production 3.9-fold over control and 2.3-fold over palbociclib (both p<0.05) and 1.7-fold over pomalidomide (p<0.01), accompanied by higher IFN-γ and TNF-α. Western blot analysis revealed that MS140 uniquely and simultaneously degraded CDK4, CDK6, and Aiolos (IKZF3), along with loss of phospho-Rb and PLK1 – a combination of effects not achieved by palbociclib or pomalidomide as single agents. Transcriptionally, MS140 imprinted a durable program that coordinately suppressed proliferative and anabolic pathways (MYC, G2M checkpoint, and mTORC1 signaling; all p<0.001) while enriched effector and persistence programs (NF-κB, IFN-γ, and IL2/STAT5 signaling; all p<0.001), consistent with elevated IL-2 protein expression. MS140 drove the strongest stem/memory transcription-factor program (TCF7, BACH2, FOXO1; all p<0.05). Metabolically, MS140 skewed CAR T cells towards oxidative phosphorylation, hallmark of stem/memory-like phenotype.
Conclusions
We present evidence that a bifunctional degrader combining CDK4/6 and IKZF1/3 degradation, during manufacturing, keeps anti-BCMA CAR-T cells in cell cycle arrest while simultaneously initiating transcriptional and metabolic programs that sustain long-term efficacy. This synergy leads to increased proliferation, cytotoxicity, and effector cytokine production across repeated antigen challenge, outperforming palbociclib and pomalidomide as single reagents. These findings highlight the potential use of MS140 during manufacturing to improve the therapeutic efficacy of CAR-T cell therapy. Further in vivo studies are underway to verify the extent of the long-term fitness enhancement and lay the groundwork for clinical translation.
DISCLOSURES
George Kladis, N/A: No relevant conflicts of interest to declare.